Air Products bid for Yingde Gases is a major test of U.S.-Chinese cross border investing.
A major court ruling underscores that what to do with Fannie Mae and Freddie Mac is a political question.
Tesla investors are ignoring significant risks ahead of Wednesday’s earnings report, the first to reflect results from SolarCity.
Gilead Sciences’s approach to the biotech deals market involves more than just waiting.
Investors bullish about a Trump capital expenditure boom must realize that buybacks, one of the bull market’s drivers, may suffer.
For a bank that says it generates nearly half its revenue from business that crosses international borders, protectionism and populism are clearly a threat.
BHP’s concentration on copper paid off in 2016, but the easy part is over.
The Swiss bank’s wealth business is doing better than rivals, though investors should question its sustainability.
The drug industry has had multiple expensive failures trying to treat Alzheimer’s disease, yet the big potential payoff keeps it searching.